Last reviewed · How we verify

Lidocaine patch 1.8% — Competitive Intelligence Brief

Lidocaine patch 1.8% (Lidocaine patch 1.8%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management.

marketed Local anesthetic Voltage-gated sodium channels Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Lidocaine patch 1.8% (Lidocaine patch 1.8%) — Scilex Pharmaceuticals, Inc.. Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission at the site of application.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lidocaine patch 1.8% TARGET Lidocaine patch 1.8% Scilex Pharmaceuticals, Inc. marketed Local anesthetic Voltage-gated sodium channels
Prilocaine 2.5% Prilocaine 2.5% Express Specialty Pharmacy marketed Local anesthetic (amide) Voltage-gated sodium channels
Dyclonine hydrochloride mucilage Dyclonine hydrochloride mucilage Peking Union Medical College Hospital marketed Local anesthetic Voltage-gated sodium channels
Bupivacaine 0.25% with Epinephrine Bupivacaine 0.25% with Epinephrine Holy Cross Hospital, Florida marketed Local anesthetic with vasopressor Voltage-gated sodium channels
Bupivacaine + Sufentanil epidural Bupivacaine + Sufentanil epidural Charles University, Czech Republic marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil)
guided injection of mepivacaine guided injection of mepivacaine Complejo Hospitalario Universitario de Granada marketed Local anesthetic (amide) Voltage-gated sodium channels
Bupivacaine with intrathecal morphine Bupivacaine with intrathecal morphine Centre Hospitalier Universitaire Vaudois marketed Local anesthetic with intrathecal opioid Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (morphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lidocaine patch 1.8% — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-patch-1-8. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: